Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer

Journal of Thoracic Disease

Volumn 4, Issue 6, 2012, Pages 562-568

  Muraki, Keiko ^a   Koyama, Ryo ^a   Honma, Yuichiro ^a   Yagishita, Shigehiro ^a   Shukuya, Takehito ^a   Ohashi, Rina ^a   Takahashi, Fumiyuki ^a   Kido, Kenji ^a   Iwakami, Shin Ichiro ^a   Sasaki, Shinichi ^a   Iwase, Akihiko ^a   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Lung cancer; Magnesium; Nephrotoxicity; Pemetrexed

Indexed keywords

CISPLATIN; CREATININE; MAGNESIUM; MANNITOL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; HUMAN; HYDRATION; LUNG NON SMALL CELL CANCER; MALE; NEPHROTOXICITY; OVERALL SURVIVAL; RETROSPECTIVE STUDY;

EID: 84873645560     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.10.16     Document Type: Article

References (19)

1. Siegel R, De Santis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
2. van Meerbeeck JP. Staging of non-small cell lung cancer: consensus, controversies and challenges. Lung Cancer 2001; 34:S95-107.
3. Yano T, Haro A, Shikada Y., et al. Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. Int J Clin Oncol 2011; 16: 287-93.
4. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
5. Johnson SW, O'Dwyer PJ. Pharmacology of cancer chemotherapy: cisplatin and its analogues. In: De Vita VT Jr, Hellman S, Rosenberg SA. Eds. Cancer, Principles and practice of oncology, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005: 344-58.
6. dos Santos N.A., Carvalho Rodrigues MA, Martins NM, et al. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 2012; 86: 1233-50.
7. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34: 1522-34.
8. Bednar L, Wcislo G, Gasowska-Bodnar A, et al. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 2008; 44: 2608-14.
9. Willox JC, McAllister EJ, Sangster G, et al. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 1986; 54: 19-23.
10. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 1993; 50: 147-58.
11. Lehane D, Winston A, Gray R., et al. The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys 1979; 5: 1393-9.
12. Haim N, Oman SD, Galai N, et al. Estimation of creatinine clearance without 24-hour urine collection - a useful guide during cisplatin therapy. Acta Oncol 1993; 32: 409-12.
13. Lajer H, Kristensen M, Hansen H.H., et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005; 56:S35-42.
14. Hayes DM, Cvitkovic E, Golbey R.B., et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372-81.
15. Frick GA, Ballentine R, Driever C.W., et al. Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis. Cancer Treat Rep 1979; 63: 13-6.
16. Santoso JT, Lucci JA 3rd, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003; 52: 13-8.
17. Tiseo M, Martelli O, Mancuso A., et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007; 93: 138-44.
18. Wolf FI, Cittadini AR, Maier JA Magnesium and tumors: ally or foe? Cancer Treat Rev 2009; 35: 378-82.
19. Parsons FM, Edwards GF, Anderson C.K., et al. Regression of malignant tumours in magnesium and potassium depletion induced by diet and haemodialysis. Lancet 1974; 1: 243-4.